Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;42(3):1421-1434.
doi: 10.1007/s12325-024-03095-2. Epub 2025 Jan 23.

Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials

Khashayar Azimpour  1 , Patricia Dorling  2 , Irene Koulinska  2 , Swati Kunduri  2 , Zhiyi Lan  3 , Julia Poritz  3 , Gabriel Tremblay  3 , Angie Raad-Faherty  3
Affiliations

Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials

Khashayar Azimpour et al. Adv Ther. 2025 Mar.

Abstract

Introduction: Fabry disease (FD) is a rare lysosomal storage disorder that is associated with pain and progressive damage to the renal, cardiac, and cerebrovascular systems. Enzyme replacement therapy (ERT) is one of the treatment options for FD and the most recently approved ERT agent, pegunigalsidase alfa, has shown clinical efficacy in three phase 3 clinical trials of adults with FD: BALANCE, BRIDGE, and BRIGHT. Recent published guidelines support the mapping of health utility state data to the EuroQol-5 Dimension-3 Level (EQ-5D-3L) index to align with the preferred methodology used by the National Institute for Health and Care Excellence (NICE). Therefore, the primary objective of this study was to estimate EQ-5D-3L values in clinical trials of pegunigalsidase alfa for FD for future cost-utility analyses.

Methods: A mixed effects model was developed to predict values derived from EQ-5D-3L for the following health states used in cost-utility analyses: no Fabry clinical event (FCE)/no pain-related adverse event (AE), pain-related AE, cardiac FCE, cerebrovascular FCE, and renal FCE.

Results: The baseline EQ-5D-3L utility value had a statistically significant (p < 0.0001) impact on utility values, whereas study, age, sex, disease type, treatment arm, kidney function, and serious AE were not statistically significant. Health state utility values with 95% confidence intervals (CI) for the final model were as follows: no FCE/no pain-related AE, 0.8005 (0.7675, 0.8334); pain-related AE, 0.7737 (0.7262, 0.8211); cardiac FCE, 0.7189 (0.6274, 0.8103); cerebrovascular FCE, 0.7923 (0.6633, 0.9212); and renal FCE, 0.6881 (0.3887, 0.9874).

Conclusions: The utility values generated by the present study are generally in line with EQ-5D values in the FD literature and can be used to inform both economic evaluations and our understanding of the impact that FD has on quality of life.

Trial registration: NCT03018730, NCT02795676, NCT03180840.

Keywords: Clinical trials; Cost–utility analyses; EQ-5D-3L; Economic evaluation; Fabry disease; Health state utility values; Mixed effects model; Pegunigalsidase alfa; QoL; Quality of life.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of Interest: Khashayar Azimpour, Patricia Dorling, Irene Koulinska, and Swati Kunduri are employees of Chiesi. Zhiyi Lan, Julia Poritz, Gabriel Tremblay, and Angie Raad-Faherty are employees of Cytel Inc.; Chiesi commissioned Cytel Inc. for the study design, analysis, and development of the manuscript. Ethical Approval: Data in this article is not identifiable; therefore, ethics committee approval was not required for this study. For the BALANCE, BRIDGE, and BRIGHT studies, an institutional review board or independent ethics committee reviewed and approved the study protocol and any amendments prior to their implementation, each study was conducted in accordance with the Declaration of Helsinki, in compliance with the approved protocol, Good Clinical Practice guidelines, and applicable regulatory requirements. Written informed consent was obtained from all study participants of the BALANCE, BRIDGE, and BRIGHT studies that included permission to use study data in future analyses. Data from the BALANCE, BRIDGE, and BRIGHT studies was obtained and accessed via Chiesi Farmaceutici S.p.A. who are owners of the data.

References

    1. Germain DP, Altarescu G, Barriales-Villa R, et al. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. Mol Genet Metab. 2022;137(1–2):49–61. 10.1016/j.ymgme.2022.07.010. - DOI - PubMed
    1. Miller JJ, Kanack AJ, Dahms NM. Progress in the understanding and treatment of Fabry disease. Biochim Biophys Acta Gen Subj. 2020;1864(1): 129437. 10.1016/j.bbagen.2019.129437. - DOI - PMC - PubMed
    1. Svarstad E, Marti HP. The changing landscape of Fabry disease. Clin J Am Soc Nephrol. 2020;15(4):569–76. 10.2215/CJN.09480819. - DOI - PMC - PubMed
    1. Mehta A, Hughes DA. Fabry disease. In: Adam MP, Mirzaa GM, Pagon RA, et al., editors. GeneReviews(®). Seattle (WA): University of Washington, Seattle; 2023. - PubMed
    1. Winter Y, Hilz M, Beuschlein F, et al. Screening for health-related quality of life and its determinants in Fabry disease: a cross-sectional multicenter study. Mol Genet Metab. 2023;140(3):107692. 10.1016/j.ymgme.2023.107692. - DOI - PubMed

MeSH terms

Associated data

LinkOut - more resources